cholesteryl palmitate : A cholesterol ester obtained by the formal condensation of cholesterol with palmitic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 246520 |
| CHEBI ID | 3663 |
| SCHEMBL ID | 295637 |
| MeSH ID | M0087317 |
| Synonym |
|---|
| zr4d53ad57 , |
| nsc 59692 |
| cholest-5-en-3-ol (3beta)-, 3-hexadecanoate |
| unii-zr4d53ad57 |
| cholest-5-en-3-ol (3beta)-, hexadecanoate |
| einecs 210-002-5 |
| cholesterol hexadecanoate |
| cholest-5-ene-3-beta-yl palmitate |
| AKOS015839810 |
| 16:0 cholesteryl ester |
| ce(16:0) |
| cholest-5-en-3beta-yl hexadecanoate |
| LMST01020005 |
| cholesteryl hexadecanoate |
| cholest-5-en-3-ol (3.beta.)-, hexadecanoate |
| nsc59692 |
| cholesterol, palmitate |
| cholesterol palmitate |
| hexadecanoic acid, cholesteryl ester |
| nsc-59692 |
| cholesteryl palmitate |
| 601-34-3 |
| cholesteryl palmitate, >=98% (hplc; detection at 205 nm) |
| CHEBI:3663 |
| palmitic acid cholesteryl ester |
| (3beta)-cholest-5-en-3-yl hexadecanoate |
| 16:0 cholesterol ester |
| (3beta)-cholest-5-en-3-ol hexadecanoate |
| palmitic acid cholesterol ester |
| BMSE000544 |
| 5-cholestene 3-palmitate |
| [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hexadecanoate |
| AKOS015915569 |
| SCHEMBL295637 |
| op0201 component cholesteryl palmitate |
| (3beta)-cholest-5-en-3-yl palmitate |
| W-105278 |
| BBJQPKLGPMQWBU-JADYGXMDSA-N |
| 3.beta.-hexadecanoyloxycholest-5-ene |
| mfcd00003638 |
| cholesteryl palmitate, 97% |
| cholesterol palmitate, >/=97% |
| cholesteryl 1-hexadecanoate |
| cholesterol ester(16:0/0:0) |
| cholesterol 1-palmitoic acid |
| cholesterol 1-hexadecanoic acid |
| cholesteryl 1-palmitoate |
| cholesteryl hexadecanoic acid |
| cholesterol 1-palmitoate |
| cholesterol ester(16:0) |
| cholesteryl palmitic acid |
| cholest-5-en-3-yl palmitate |
| hexadecanoic acid cholesteryl ester |
| cholesteryl 1-hexadecanoic acid |
| cholesteryl 1-palmitoic acid |
| cholesterol 1-hexadecanoate |
| 1-palmitoyl-cholesterol |
| HY-W010708 |
| CS-W011424 |
| DS-4666 |
| 16:0(ce) |
| Q27068156 |
| (3s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-((r)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl palmitate |
| D95354 |
| DTXSID40889356 |
| cholest-5-en-3-ol (3.beta.)-, 3-hexadecanoate |
| (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-((r)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl palmitate |
| Role | Description |
|---|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| cholesteryl ester | A sterol ester obtained by formal condensation of the carboxy group of any carboxylic acid with the 3-hydroxy group of cholesterol. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Cholesterol Biosynthesis and Metabolism CE(16:0) | 22 | 50 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (22.73) | 18.7374 |
| 1990's | 9 (40.91) | 18.2507 |
| 2000's | 2 (9.09) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.46) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||